Advertisement

Exkurs: Neue klinische Entwicklungen

  • Th. Müller
  • W. Kuhn

Zusammenfassung

Die Umwandlung der Aminosäure Tyrosin in L-Dopa durch das Enzym Tyrosinhydroxylase ist der geschwindigkeitsbestimmende Schritt der Biosynthese von Dopamin. Ein verminderter Gehalt an Tyrosinhydroxylase als auch eine erniedrigte Konzentration des Co-Enzyms Tetrahydrobiopterin (BH4) ist bei Parkinson-Patienten im nigrostriatalen System aufgrund der Degeneration praesynaptischer Neurone nachgewiesen worden (McGeer und McGeer 1971, Lloyd et al. 1975, Nagatsu et al. 1984, Sawada et al. 1985, Fujishiro et al. 1990, Nagatsu 1993). Aufgrund der relativ schwachen Permeation von BH4 durch die Bluthirnschranke waren Behandlungsversuche mit (BH4) zur Stimulierung der Aktivität der Tyrosinhydroxylase wenig erfolgreich (Yamaguchi et al. 1983). Eine andere Möglichkeit besteht in der Verwendung von NADH.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Birkmayer JG, Vrecko C, Volc D, Birkmayer W (1993) Nicotinamide adenine dinucleotide (NADH) — a new therapeutic approach to Parkinson’s disease. Comparison of oral and parenteral application. Acta Neurol Scand [Suppl] 146: 32–35Google Scholar
  2. Birkmayer W, Birkmayer GJ (1989) Nicotinamid-adenindinucleotide (NADH): the new approach in the therapy of Parkinson’s disease. Ann Clin Lab Sci 19: 38–43PubMedGoogle Scholar
  3. Birkmayer W, Birkmayer GJ, Vrecko K, Mlekusch W, Paletta B, Ott E (1989) The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of parkinsonian patients. J Neural Transm [PD Sect] 1: 297–302CrossRefGoogle Scholar
  4. Birkmayer W, Birkmayer JG, Vrecko K, Paletta B (1990) The clinical benefit of NADH as stimulator of endogenous L-dopa biosynthesis in parkinsonian patients. Adv Neurol 53: 545–549PubMedGoogle Scholar
  5. Dizdar N, Kagedal B, Lindvall B (1994) Treatment of Parkinson’s disease with NADH. Acta Neurol Scand 90: 345–347PubMedCrossRefGoogle Scholar
  6. Fujishiro K, Hagihara M, Takahashi A, Nagatsu T (1990) Concentrations of neopterin and biopterin in the cerebrospinal fluid of patients with Parkinson’s disease. Biochem Med Metab Biol 44: 97–100PubMedCrossRefGoogle Scholar
  7. Kuhn W, Müller T, Winkel R, Danielczik S, Gerstner A, Hacker A, Mattern C, Przuntek H (1996) Parenteral application of NADH in Parkinson’s disease. Clinical improvement partially due to stimulation of endogenous levodopa biosynthesis. J Neural Transm 103: 1187–1196PubMedCrossRefGoogle Scholar
  8. Lloyd KG, Davidson L, Hornykiewicz O (1975) The neurochemistry of Parkinson’s disease: effect of L-dopa therapy. J Pharmacol Exp Ther 195: 453–464PubMedGoogle Scholar
  9. Maruyama W, Naoi M, Narabayashi H (1994) Study on the metabolism of droxidopa in humane. Rinsho Shinkeigaku 34: 991–995PubMedGoogle Scholar
  10. Mattern C (1995) Zur Entwicklung von stabilen Arzneiformen des Coenzyms NADH für die perorale und parenterale Applikation. Dissertation, Humboldt-Universität, BerlinGoogle Scholar
  11. Mcgeer PL, Mcgeer EG (1971) Cholinergic enzyme systems in parkinson’s disease. Arch Neurol 25: 265–268PubMedCrossRefGoogle Scholar
  12. Nagatsu T, Yamaguchi T, Rahman MK, Trocewicz J, Oka K, Hirata Y, Nagatsu I, Narabayashi H, Kondo T, Iizuka R (1984) Catecholamine-related enzymes and the biopterin cofactor in Parkinson’s disease and related extrapyramidal diseases. Adv Neurol 40: 467–473PubMedGoogle Scholar
  13. Nagatsu T (1993) Enzymatic stimulation and enzymatic inhibition in Parkinson’s disease. Acta Neurol Scand [Suppl] 146: 14–17Google Scholar
  14. Sawada M, Nagatsu T, Nagatsu I, Ito K, Iizuka R, Kondo T, Narabayashi H (1985) Tryptophan hydroxylase activity in the brains of controls and parkinsonian patients. J Neural Transm 62: 107–115PubMedCrossRefGoogle Scholar
  15. Vrecko K, Birkmayer JG, Krainz J (1993) Stimulation of dopamine biosynthesis in cultured PC 12 phaeochromocytoma cells by the coenzyme nicotinamide adeninedinucleotide (NADH). J Neural Transm [PD Sect] 5: 147–156CrossRefGoogle Scholar
  16. Yamaguchi T, Nagatsu T, Sugimoto T, Matsuura S, Kondo T, Iizuka R, Narabayashi H (1983) Effects of tyrosine administration on serum biopterin in normal controls and patients with Parkinson’s disease. Science 219: 75–77PubMedCrossRefGoogle Scholar

Literatur

  1. Bonnet AM, Loria Y, Saint Hilaire MR, Lhermitte F, Agid Y (1987) Does long-term aggravation of Parkinson’s disease result from non-dopaminergic lesions? Neurology 37: 1539–1542PubMedCrossRefGoogle Scholar
  2. Braak H, Braak E, Yilmazer D, De Vos RAI, Jansen ENH (1995) Nigral and extranigral pathology in parkinson’s disease. J Neural Transm 46 [Suppl]: 15–32Google Scholar
  3. Katsube J, Narabayashi H, Hayashi A, Tanaka C, Suzuki T (1994) Development of L-threo-DOPS, a norepinephrine precursor amino acid. Yakugaku Zasshi 114: 823–846PubMedGoogle Scholar
  4. Kondo T (1984) D,L-threo-3,4-dihydroxyphenylserine (D,L-threo-DOPS) treatment on the patients with Parkinson’s disease or pure akinesia. Rinsho Shinkeigaku 24: 280–288PubMedGoogle Scholar
  5. Kondo T (1993) L-threo-DOPS in advanced parkinsonism. Adv Neurol 60: 660–665PubMedGoogle Scholar
  6. Maruyama W, Naoi M, Narabayashi H (1994) Study on the metabolism of droxidopa in humane. Rinsho Shinkeigaku 34: 991–995PubMedGoogle Scholar
  7. Nakajima Y, Kagamihara Y, Nagaoka M, Tanaka R (1987) The effect of L-threo-DOPS on synaptic transmission to soleus motoneuron in normal subjects and patients with Parkinson’s disease. Neurosci Res 5: 16–27PubMedCrossRefGoogle Scholar
  8. Narabayashi H (1983a) Mechanism of the development of akinesia in Parkinson’s disease-with reference to L-threo-DOPS therapy. No To Shinkei 35: 1057–1063PubMedGoogle Scholar
  9. Narabayashi H (1983b) Pharmacological basis of akinesia in Parkinson’s disease. J Neural Transm [Suppl] 19: 143–151Google Scholar
  10. Narabayashi H, Yokochi F, Ogawa T, Igakura T (1991) Analysis of L-threo-3,4dihydroxy-phenylserine effect on motor and psychological symptoms in Parkinson’s disease. No To Shinkei 43: 263–268PubMedGoogle Scholar
  11. Pillon B, Dubois B, Bonnet AM, Esteguy M, Guimaraes J, Vigouret JM, Lhermitte F, Agid Y (1989a) Cognitive slowing in Parkinson’s disease falls to respond to levodopa treatment: the 15-objects fest. Neurology 39: 762–768PubMedCrossRefGoogle Scholar
  12. Pillon B, Dubois B, Cusimano G, Bonnet AM, Lhermitte F, Agid Y (1989b) Does cognitive impairment in Parkinson’s disease result from non-dopaminergic lesions? J Neurol Neurosurg Psychiatry 52: 201–206PubMedCrossRefGoogle Scholar
  13. Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in Parkinson’s disease. J Neural Transm [Gen Sect] 38: 277–301CrossRefGoogle Scholar
  14. Suzuki T, Sakoda S, Ueji M, Kishimoto S, Hayashi A, Kondo T, Narabayashi H (1984) Treatment of parkinsonism with L-threo-3,4-dihydroxy-phenylserine: a pharmacokinetic study. Neurology 34: 1446–1450PubMedCrossRefGoogle Scholar
  15. Tohgi H, Abe T, Takahashi S (1993) The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients. J Neural Transm [PD Sect] 5: 27–34CrossRefGoogle Scholar
  16. Verhagen Kamerbeek WD, Hazemeijer I, Korf J, Lakke JP (1993) Attenuation of haloperidol-induced catalepsy by noradrenaline and L-threo-DOPS. J Neural Transm [PD Sect] 6: 17–26CrossRefGoogle Scholar

Literatur

  1. Arevalo GJ, Gershanik OS (1993) Modulatory effect of clozapine on levodopa response in Parkinson’s disease: a preliminary study. Mov Disord 8: 349–354PubMedCrossRefGoogle Scholar
  2. Baldessarini RJ, Frankenburg FR (1991) Clozapine. A novel antipsychotic agent. N Engl J Med 324: 746–754PubMedCrossRefGoogle Scholar
  3. Bennett JP Jr, Landow ER, Schuh LA (1993) Suppression of dyskinesias in advanced Parkinson’s disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 43: 1551–1555PubMedCrossRefGoogle Scholar
  4. Bennett JP Jr, Landow ER, Dietrich S, Schuh LA (1994) Suppression of dyskinesias in advanced Parkinson’s disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord 9: 409–414PubMedCrossRefGoogle Scholar
  5. Bowman CE (1995) Drug-licensing aromalies and Parkinson’s disease. Lancet 345: 517PubMedCrossRefGoogle Scholar
  6. Diederich N, Keipes M, Graas M, Metz H (1995) Clozapine in the treatment of mental manifestations of Parkinson disease. Rev Neurol Paris 151: 251–257PubMedGoogle Scholar
  7. Doraiswamy M, Martin W, Metz A, Deveaugh Geiss J (1995) Psychosis in Parkinson’s disease: diagnosis and treatment. Prog Neuropsychopharmacol Biol Psychiatry 19: 835–846PubMedCrossRefGoogle Scholar
  8. Dose M (1994) Genehmigungspflicht einer Behandlung mit Clozapin nach Paragraph 1904 des Betreuungsrechts? Nervenarzt 65: 787–791PubMedGoogle Scholar
  9. Ellenbroek B, Prinssen E, Cools A (1992) The azophenothiazine prothipendyl is an atypical neuroleptic acting through D1 and D2 receptors. Neurosci Res Comm 11/3: 155–161Google Scholar
  10. Factor SA, Molho ES, Brown DL (1995) Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 7: 304–307PubMedGoogle Scholar
  11. Friedman JH, Lannon MC (1990) Clozapine-responsive tremor in Parkinson’s disease. Mov Disord 5: 225–229PubMedCrossRefGoogle Scholar
  12. Ghika J (1995) Initiation of treatment in Parkinson disease. Schweiz Rundsch Med Prax 84:1018–1020Google Scholar
  13. Gonski PN (1994) The use of clozapine in Parkinson’s disease. Aust NZ J Med 24: 585CrossRefGoogle Scholar
  14. Greene P (1995) Clozapine therapeutic plunge in patient with Parkinson’s disease. Lancet 345: 1172–1173PubMedCrossRefGoogle Scholar
  15. Gross R, Amital D (1995) Clozapine in the treatment of tremor in Parkinson’s disease. Acta Neurol Scand 91: 225PubMedCrossRefGoogle Scholar
  16. Jansen EN (1994) Clozapine in the treatment of tremor in Parkinson’s disease. Acta Neurol Scand 89: 262–265PubMedCrossRefGoogle Scholar
  17. Kraus P, Aubel T, Wessel K, Klotz P, Börnke C, Langkafel M, Przuntek H (1995) Antitremor effect of prothipendyl (Dominai®) in patients with idiopathic tremor-dominant parkinsonian syndrome, J Neurol [Suppl] 2/242/6: 740Google Scholar
  18. Meltzer HY (1995) Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 3: 64–75PubMedGoogle Scholar
  19. Meltzer HY, Kennedy J, Dai J, Parsa M, Riley D (1995) Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson’s disease. A high potency effect of clozapine. Neuropsychopharmacology 12: 39–45PubMedGoogle Scholar
  20. Pfeiffer C, Wagner ML (1994) Clozapine therapy for Parkinson’s disease and other movement disorders. Am J Hosp Pharm 51: 3047–3053PubMedGoogle Scholar
  21. Rabey JM, Treves TA, Neufeld MY, Orlov E, Korczyn AD (1995) Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson’s disease. Neurology 45: 432–434PubMedCrossRefGoogle Scholar
  22. Rich SS, Friedman JH, Ott BR (1995) Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson’s disease and other akinetic-rigid syndromes. J Clin Psychiatry 56: 556–559PubMedGoogle Scholar
  23. Seeman P (1992) Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 7: 261–284PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • Th. Müller
  • W. Kuhn

There are no affiliations available

Personalised recommendations